CA
RIGL icon

Continuum Advisory’s Rigel Pharmaceuticals RIGL Stock Holding History

Continuum Advisory’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-58
Closed -$596 – 1743
2024
Q1 		$596 Buy
+58
New +$782 ﹤0.01% 1571

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Continuum Advisory's RIGL Position: Q2 2024 in Review

Continuum Advisory sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 58 shares — an estimated $596 sold.

Continuum Advisory first reported a position in RIGL in Q1 2024 and held it in 1 quarter. The position peaked at $596 in Q1 2024. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Continuum Advisory reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Continuum Advisory sold 58 Rigel Pharmaceuticals shares in Q2 2024, an estimated $596.
  • Continuum Advisory first reported a position in Rigel Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Continuum Advisory's Rigel Pharmaceuticals position peaked at $596 in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Continuum Advisory's 13F filing for Q2 2024, filed 19 Jul 2024.